Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis

Abstract

The objective of the present study is to evaluate the effect of the extract of a well-known hepatospecific polyherbal formulation, Liv.52, in an experimental model of high-fat diet (HFD)-induced nonalcoholic steatohepatitis (NASH) in rats. Feeding a HFD for 15 weeks resulted in significant impairment of the lipid profile, elevation of hepatic enzyme markers, and insulin resistance in rats. The histological examination of the liver furthermore indicated fibrotic changes and fat deposition in hepatic tissues. The treatment with Liv.52 extract [125 mg/kg body weight per os (b.wt. p.o.)], which was administered from week 9 onward, reversed the HFD-induced changes to a statistically significant extent, compared to the untreated positive control animals. The effect observed with Liv.52 extract was comparable to that of pioglitazone (4 mg/kg b.wt.), a standard drug that is useful in the management of NASH. The treatment with Liv.52 extract significantly reduced steatosis, collagen deposition, and necrosis in hepatic tissues, which indicates its antifibrotic and antinecrotic properties. The results obtained in the present set of experiments indicate that Liv.52 extract effectively reverses metabolic and histological changes associated with HFD-induced NASH.

Treatment with a polyherbal extract improves fat metabolism, attenuates hepatic stellate cell activation and fibrogenesis

“…Earlier studies have established the effect of Liv.52 in NASH and cirrhosis[6,7] and our studies demonstrate that Liv.52 exerts its effect against NASH by influencing aforementioned pathways. Taken together our study establishes the mechanism behind anti-NASH and anti-fibrotic effects of Liv.52.…”

“…The Liv.52 extract constitutes a mixture of Capparis spinosa (roots), Cichorium intybus (seeds), Solanum nigrum (whole plant), Terminalia arjuna (bark), Cassia occidentalis (seeds), Achillea millefolium (aerial part), and Tamarix gallica (whole plant). Preparation of Liv.52 extract and its detailed LC-MS/MS analysis are described earlier[6,8]. Briefly, the crude herbal materials were pulverized and the coarse powders obtained were blended.…”

“…Liv.52 is a polyherbal formulation approved by the Government of India’s Drug Regulatory Authority, the department of Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) of the Ministry of Health and Family Welfare (New Delhi, India). Clinical and preclinical studies indicate its efficacy as a hepatoprotective agent in NASH and cirrhosis[6,7].…”

Co-administration effects of aqueous extract of turnip leaf and metformin in diabetic rats

“… 28 A huge number of evidence indicates that diabetes is associated with a wide range of liver abnormalities including abnormal glycogen deposition, non-alcoholic fatty liver disease (NAFLD), fibrosis, cirrhosis, hepatocellular carcinomas, abnormal elevated liver enzymes, acute liver disease and viral hepatitis. 29 , 30 , 31 …”

A standardized polyherbal preparation POL-6 diminishes alcohol withdrawal anxiety by regulating Gabra1, Gabra2, Gabra3, Gabra4, Gabra5 gene expression of GABAA receptor signaling pathway in rats

“…The conditions for the solvent system were 20:80 ratios, flow rate of 1.5 ml/min, and a run time of approximately 45 min. The chromatogram was obtained at a wavelength of 227 nm [ 20 ].…”